EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Hyperfine Inc (HYPR) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Hyperfine Inc $0.40, price $0.79, upside -49.4%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US44916K1060

HI Hyperfine Inc logo Thin data Sep 24, 2026

Hyperfine Inc

HYPR · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.4000 · Strongly overvalued (−49%)
!Quality 38/100
!Mixed Growth (revenue 5y +115.2 %/yr)
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.92 $0.5448 Fair Value $0.4000 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.5448 – $10.92 · fair‑value band $0.2700 – $0.5000 · the $0.7900 price screens above the $0.4000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Hyperfine in your weekly email

Every Wednesday you see whether Hyperfine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.

Show more

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.

Stock analysis

Hyperfine Inc (HYPR) currently trades at $0.7900, while our model-based Fair Value estimate is $0.4000, implying the stock looks roughly 97.5% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $0.2700 (bear) to $0.5000 (bull), the price of $0.7900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hyperfine Inc reported revenue of $13.6M in FY2025 versus $1.5M in FY2021, a compound +73.5%/yr. Reported net income was −$35.6M in FY2025.

Key figures

Market cap $78.8M · P/S ratio 5.14 · EPS (TTM) $−0.3700 · Net margin −211% · Return on equity −97.0% · Return on assets (EBIT) −55.7% · Operating margin −217% · Revenue (TTM) $16.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 64% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −49%, HYPR screens richer than that median.

Fair Value models

Bear $0.2700 Fair Value $0.4000 Bull $0.5000
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.2300 $0.3000 $0.4500 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.2300 $0.3000 $0.4500 51

Open the full fair value analysis →

Notify me when HYPR reaches fair value

Put HYPR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 38/100

Of which business quality 40 · Market factors (momentum, volatility) 5

Profitability 6
Margins and returns on capital today
Quality Growth 77
Are margins and returns improving?
Cashflow 6
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 15
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 10
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+115.2%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7,990.1% (2020) → −273.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HYPR screens 98% overvalued. Compare with Abbott Laboratories, →

Compare Hyperfine Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −49% · Below median
Profitability
Return on assets −39% · Bottom 25%
Growth and dividend
Revenue growth 45% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.92× · Pricier than median
P/S (TTM) 4.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.49 $74.79 −28%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Hyperfine Inc Fair Value". https://www.fairvalue-calculator.com/stock/HYPR

Frequently asked questions

Is Hyperfine Inc (HYPR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.4000 versus a price of $0.7900, about −49% upside (overvalued).
What is the fair value of HYPR?
Our model-based fair value for Hyperfine Inc is $0.4000 (as of Sep 24, 2026), built from audited fundamentals. The current price: $0.7900.
What is the quality score of HYPR?
Hyperfine Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hyperfine Inc (HYPR)?
Our model-based price target is the fair value of $0.4000 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.2700, optimistic scenario $0.5000. It is a calculation from audited fundamentals, not an analyst target.
What is the Hyperfine Inc stock forecast for 2026?
Our models put fair value at $0.4000, about −49% upside versus a price of $0.7900 (overvalued). Cautious scenario $0.2700, optimistic scenario $0.5000. The calculation is refreshed regularly with new filings.
What is the revenue of Hyperfine Inc (HYPR)?
Hyperfine Inc reported trailing-twelve-month revenue of about $16.5M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Hyperfine Inc (HYPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hyperfine Inc it is $0.4000 per share (as of Sep 24, 2026), against a price of $0.7900. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Hyperfine Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HYPR trades above its calculated fair value: price $0.7900, fair value $0.4000, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HYPR?
No. The price is what the market pays today ($0.7900); the fair value is what the company's own numbers justify ($0.4000). For Hyperfine Inc the two are $0.3900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hyperfine Inc worth?
The market values Hyperfine Inc at about $78.8M (market capitalisation, as of Sep 24, 2026). Per share that is $0.7900; our models calculate a fair value of $0.4000 per share.
What do the bullish and bearish scenarios say about HYPR?
Our models span a range for Hyperfine Inc: cautious scenario $0.2700, base $0.4000, optimistic $0.5000 per share (as of Sep 24, 2026, price $0.7900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hyperfine Inc (HYPR)?
Balance-sheet figures for Hyperfine Inc (as of Sep 24, 2026): return on equity −97.0%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is HYPR from its 52-week high?
Hyperfine Inc trades at $0.7900, about 64% below its 52-week high of $2.20 and 2% above the low of $0.7728 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4000 is for.
Which stocks are comparable to Hyperfine Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hyperfine Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $0.7900, calculated fair value $0.4000 (−49%), Quality Score 38/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HYPR calculated?
We run Hyperfine Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Hyperfine Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hyperfine Inc (HYPR)?
The closing price on Sep 23, 2026 was $0.7900. Our model-based fair value is $0.4000, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hyperfine Inc right now?
The price sits above even our optimistic bull case ($0.5000). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2700 to $0.5000) leaves room in how you read the outcome.

Key figures of Hyperfine Inc

How large is the market capitalisation of Hyperfine Inc (HYPR)?
The market capitalisation of Hyperfine Inc is $78.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hyperfine Inc (HYPR)?
The price-to-sales ratio of Hyperfine Inc is 5.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hyperfine Inc (HYPR)?
Earnings per share at Hyperfine Inc are $−0.3700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hyperfine Inc (HYPR)?
The net margin of Hyperfine Inc is −211% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hyperfine Inc (HYPR)?
The return on equity (ROE) of Hyperfine Inc is −97.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hyperfine Inc (HYPR)?
On an EBIT basis the return on assets of Hyperfine Inc is −55.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hyperfine Inc (HYPR)?
The operating margin of Hyperfine Inc is −217% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hyperfine Inc (HYPR)?
Revenue at Hyperfine Inc is growing +44.8% versus a year earlier (3y avg +25.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Hyperfine Inc (HYPR) generate?
The free cash flow of Hyperfine Inc is −$29.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Hyperfine Inc (HYPR) hold?
Hyperfine Inc holds more cash than debt, $34.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Hyperfine Inc in the live analysis

One click puts Hyperfine Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.